This week’s articles describe why pulmonary hypertension often arises with lung cancer; a way to interrupt the autoimmune response in type 1 diabetes; and a marker through which to screen patients for response to MSC therapy and risk for graft-versus-host disease.
CANCER
A tense environment
Pullamsetti et al. report that lung cancer drives vascular remodeling in its microenvironment, resulting in the development of pulmonary hypertension in patients.
AUTOIMMUNITY
Stemming attacks on the pancreas
Ben Nasr et al. demonstrate that gene therapy or pharmacological enhancement of PD-L1 on hematopoietic stem cells could suppress the autoimmune-mediated pancreatic β cell loss in patients with diabetes.
TRANSPLANTATION
MSC sacrifice for immunosuppression
Galleu et al. show that patients could be screened for the capacity of their phagocytes to kill mesenchymal stromal cells to predict their response to a therapeutic transplant.
